CRISPR Therapeutics AG 8-K

What Happened
CRISPR Therapeutics AG announced on March 16, 2026 that it completed a previously announced private offering of $600.0 million aggregate principal amount of Convertible Senior Notes due 2031 (including full exercise of a $50.0 million option). The Notes were issued under an indenture with U.S. Bank Trust Company, N.A. as trustee. Because of an anticipated 35% Swiss withholding on interest, the effective coupon was increased from 1.125% to 1.7308% to offset the withholding for holders not eligible for refunds. Net proceeds to the company were approximately $585.2 million, which CRISPR says it will use for general corporate purposes.

Key Details

• Offering size: $600.0 million principal (initial purchasers’ option exercised in full for additional $50.0M).
• Net proceeds: ~ $585.2 million after discounts, commissions and expenses.
• Coupon/interest: 1.125% stated, effectively 1.7308% after the withholding adjustment; interest paid semiannually on March 1 and September 1, starting Sept 1, 2026.
• Maturity and conversion: Notes mature March 1, 2031; initial conversion rate 13.0617 Common Shares per $1,000 principal (initial conversion price ≈ $76.56/share, ~45% premium to the $52.80 last reported sale on Mar 10, 2026). Initially up to 11,363,580 Common Shares may be delivered upon conversion based on the initial maximum conversion rate.
• Redemption/repurchase: Company may not redeem before Mar 6, 2029; optional cash redemption permitted thereafter subject to share-price conditions (130% test). Holders can require repurchase on a fundamental change at 100% of principal plus accrued interest. Notes are senior, unsecured; customary covenants and events of default apply.

Why It Matters
For investors, this filing shows CRISPR raised substantial cash (~$585M) while taking on convertible debt rather than issuing straight equity. The Notes carry a low effective cash interest cost but can convert into Common Shares at a premium, meaning potential dilution (up to the initially stated ~11.36M shares) if conversions occur. The debt increases the company’s financial obligations through 2031 and includes limits on early redemption until 2029; large cash proceeds can support R&D, operations, or pipeline advancement without immediate equity dilution.